OMEICOS Therapeutics GmbH’s Post

Good news from @omeicos on the currently running clinical phase 2 trial in rare disease indication Primary Mitochondrial Disease: - enrollment in PMD-OPTION study completed - enrollment target met - strong safety and tolerability of OMT-28 shown and - on track for top-line results next year. Great commitment by patients for our study and big achievement of the whole PMD-OPTION study teams at the clinical sites, the CROs and at OMEICOS #teamwork #mitochondrialdisease #clinicalstudy

🚨 ICYMI our co-founder, Dr Tim Jobson, recently penned an insightful article published by pharmaphorum all about the increasing challenges that face sponsors running clinical trials for Metabolic Associated Steatohepatitis (MASH). With over 2 million deaths from liver disease last year, MASH research faces hurdles like limited participant pools and a lack of experienced trial sites. However, innovative tools, like our hepatoSIGHT, could enhance early detection and streamline recruitment. Read the full article now 👉  https://lnkd.in/eHyRuUtb #ClinicalTrials #MASH #NASH #LiverDisease

I was honored to deliver a keynote address at the World Orphan Drug Congress USA in Boston yesterday, focused on the opportunity to drive innovation and increase treatment options in rare diseases. Innovation in clinical trial design, evidence generation and evaluation are necessary steps in improving access to therapy for people living with rare diseases. But first, there needs to be alignment across stakeholder groups. If we can collectively agree on the use of evidence generation and interpretation methods, then we can better address the complex challenges in rare diseases, advance new medicines for patients, and ultimately bring better care for rare. #raredisease #orphandrug #WorldOrphanUSA

As Scientific Director at CoRE, a new clinic at Mount Sinai in NYC, PolyBio President Dr. Amy Proal designs and implements clinical trials for Infection-Associated Complex Chronic Condition (#IACC) patients. Along with David Putrino, she’s investigating repurposed HIV-antivirals Truvada & Maraviroc as potential Long COVID treatments and the fibrinolytic enzyme Lumbrokinase to treat Long COVID, ME/CFS and Lyme+. She speaks regularly with the CoRE scientific team on key issues surrounding complex chronic illness. This video series is a part of an ongoing effort at CoRE to educate patients on the mechanisms of their chronic conditions. You can access these free seminars here 👇🏻: https://lnkd.in/e6EXrD6c #longcovid #infectionassociatedchronicillness #mecfs #lyme+

Rare diseases need rare solutions. Think treating rare diseases is too complex? AnzuBridge is breaking barriers with next-generation solutions that enhance the efficacy of clinical trials for rare diseases. By integrating advanced data capture, analysis, and media review, AnzuBridge ensures every patient's data contributes to comprehensive insights and more effective treatments. Convinced yet? With precise and efficient evaluations, AnzuBridge's technology is not just innovative; it's a game-changer for those at the forefront of rare disease research. Ready to see how AnzuBridge can revolutionize your clinical trials? Contact us today to learn more and join the movement towards better treatment options for rare diseases. #clinicaltrials #clinicaltrialvideo #mediacapture #medtech #healthcare #medicaltechnology #clinicaltrialprofessionals #cro #clinicalresearch

🌟 PICO Forecasting: A Game-Changer for Orphan Drugs in Rare Diseases   Rare diseases demand unique and tailored pricing and access strategies, and Akceso’ PICO forecasting provides the precision needed to address these challenges. By focusing on patient-centered outcomes and precise interventions, this methodology enables you to:   ✔️ Accelerate time-to-patients for innovative treatments. ✔️ Address unmet medical needs with payer-relevant evidence insights ✔️ Drive impactful decisions for niche but important patient populations.   PICO forecasting is more than just a methodology—it’s a tool for better care and better lives. Let’s work together to make a difference — contact us here: https://akceso.ch/contact/   #PICOForecasting #RareDiseases #PatientCentric

Having the right and enough #biospecimens for your research is often a challenge. Our disease-state leukopaks provide billions of cells from a single donor. ✔️ Fresh or cryopreserved ✔️ 30+ diagnosed conditions including SLE , #rheumatoidarthritis, #multiplesclerosis, and Myasthenia Gravis ✔️ Comprehensive donor data Explore how you can accelerate your therapeutic development: https://lnkd.in/dyWYKgFC #celltherapy #genetherapy #sanguineleukopaks

$IMMX IMMIX: Positive Clinical Data FromFirst 4 patients in the CAR-T trial for amyloidosis achieved normalized disease markers! 🎉 2 are complete responders, and 2 are bone marrow negative. ⌛️next program update in H1 2025. Interim clinical data expected Q2/Q3 2025. Final topline clinical data expected Q2/Q3 2026 #Biotech #Healthcare https://lnkd.in/gFHqAsM9

Update on ePROVIDE scientific collaborations The PROQOLID database, which details information on Clinical Outcome Assessments (COAs), is now connected to two additional scientific sources of information, where applicable: - COSMIN: Check the systematic reviews that mention the Clinical Outcome Assessment you plan to use in your study. - Orphanet disease database: Find more information on the rare disease you are investigating. Test PROQOLID now: https://lnkd.in/eAjJp-Z4 Learn more about COSMIN database of systematic reviews: https://lnkd.in/et-_rctw Visit the Orphanet rare disease database: https://lnkd.in/eGCa6GFi #ePROVIDE #ClinicalOutcomeAssessments #PROMs #RareDiseases

A new article about adalimumab response and HS, which was published in JAAD and is titled ‘Circulating monocytes as a marker of response to adalimumab in patients with hidradenitis suppurativa’. Read more.. https://lnkd.in/e7dU6xYR